regadenoson has been researched along with adenosine in 54 studies
| Studies (regadenoson) | Trials (regadenoson) | Recent Studies (post-2010) (regadenoson) | Studies (adenosine) | Trials (adenosine) | Recent Studies (post-2010) (adenosine) |
|---|---|---|---|---|---|
| 321 | 53 | 264 | 32,536 | 1,075 | 8,930 |
| Protein | Taxonomy | regadenoson (IC50) | adenosine (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 0.3851 | |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.5 | |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | 5.5 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.0011 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0023 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 63 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (25.93) | 29.6817 |
| 2010's | 35 (64.81) | 24.3611 |
| 2020's | 5 (9.26) | 2.80 |
| Authors | Studies |
|---|---|
| Deflorian, F; Gao, ZG; Jacobson, KA; Katritch, V; Kumar, TS; Phan, K; Stevens, RC; Wu, H; Xu, F | 1 |
| de Lera Ruiz, M; Lim, YH; Zheng, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fan, S; Li, S; Xie, F; Zhang, M; Zhong, W; Zhou, X | 1 |
| Baker, SP; Belardinelli, L; Blackburn, B; Elzein, E; Gao, Z; Lasley, RD; Li, Z; Meyer, S; Palle, V; Zablocki, JA | 1 |
| Belardinelli, L; Belloni, F; Hintze, TH; Linke, A; Ochoa, M; Xu, X; Zhao, G | 1 |
| Bateman, TM; Blackburn, B; Cerqueira, MD; Hendel, RC; Iskandrian, AE; Leppo, JA; Mahmarian, JJ | 1 |
| Cerqueira, MD | 1 |
| Mitka, M | 1 |
| Botvinick, EH | 1 |
| Belardinelli, L; Blackburn, B; Franks, B; Hage, FG; Heo, J; Iskandrian, AE; Wang, W | 1 |
| Druz, RS | 1 |
| Cerqueira, MD; Iskandrian, AE; Nguyen, P; Staehr, P; Underwood, SR | 1 |
| Udelson, JE | 2 |
| Bateman, TM; Cerqueira, MD; Hendel, RC; Iskandrian, AE; Mahmarian, JJ; Moye, LA; Olmsted, AW; Thomas, GS | 1 |
| Belardinelli, L; Dione, DP; Jadbabaie, F; Mekkaoui, C; Meoli, DF; Purushothaman, K; Sinusas, AJ | 1 |
| Dilsizian, V | 1 |
| Curran, MP; Garnock-Jones, KP | 1 |
| Hage, FG; Heo, J; Iskandrian, AE; Perry, G | 1 |
| Belardinelli, L; Clarke, KA; Miyamoto, MI; Thomas, GS | 1 |
| Ananthasubramaniam, K; Barboza, J; Cavalcante, JL | 1 |
| Adluru, G; Chen, L; DiBella, EV; Fluckiger, JU; Jiji, R; Kim, TH; Kuppahally, S; Litwin, SE; Matthews, B; McGann, C; Pack, NA; Priester, T | 1 |
| Pijls, NH; Tonino, PA | 1 |
| Ahmed, A; Dean, PJ; Hage, FG; Heo, J; Iqbal, FM; Iskandrian, AE; Raslan, S | 1 |
| Arumugham, P; Figueredo, VM; Morris, DL; Patel, PB | 1 |
| Boulanger, L; Friedman, M; Gatt, E; Kothari, S; Spalding, J; Wu, Y | 1 |
| Clavijo, LC; Doherty, R; Gopal, A; Matthews, RV; Mehra, A; Prasad, A; Shavelle, DM; Somma, K; Vora, H; Zareh, M | 1 |
| Biederman, RW; Dishart, MK; Doyle, M; Fakhri, AA; Grant, SB; Nathan, S; Oliva, J; Poydence, J; Reddy, ST; Shah, M; Singh, A; Thai, NL; Tom, KB; Williams, RB; Yamrozik, JA | 1 |
| Arai, AE; Bandettini, WP; Booker, OJ; Hsu, LY; Kellman, P; Leung, S; Mancini, C; Shanbhag, SM; Vasu, S; Wilson, J | 1 |
| Dziuk, M; Kocki, J; Pińkowski, R; Tkaczewski, K | 1 |
| Kinser, CR; Kristy, R; Mahmarian, JJ; Thomas, GS; Xu, J | 1 |
| Bremerich, J; Kawel-Boehm, N | 1 |
| Hakeem, A; Uretsky, B | 1 |
| Bayer, RR; De Cecco, CN; Harris, BS; Krazinski, AW; McWhite, CB; Meinel, FG; Schoepf, UJ; Silverman, JR | 1 |
| Bateman, TM; Cerqueira, MD; Iskandrian, AE; Mahmarian, JJ; Nabi, F; Peterson, LE; Thomas, GS; Xu, J | 1 |
| Amano, T; Doh, JH; Kato, D; Kim, HS; Koo, BK; Kurita, A; Lim, WH; Nam, CW; Oi, M; Park, JJ; Park, KW; Pijls, NH; Takashima, H; Toyofuku, M; van Nunen, L; Waseda, K; Yang, HM | 1 |
| Captur, G; Greenwood, JP; Herrey, AS; Manisty, C; Moon, JC; Peebles, C; Petersen, SE; Plein, S; Ripley, DP; Schelbert, EB; Wong, TC | 1 |
| Borges-Neto, S; Dunning, A; Farzaneh-Far, A; O'Connor, CM; Oldan, JD; Shaw, LK | 1 |
| Basu, S | 1 |
| Brink, HL; Dickerson, JA; Pickworth, KK; Stephens, JA | 1 |
| Kawaji, K; Kramer, CM; Lang, RM; Mor-Avi, V; Nathan, S; Patel, AR; Patel, MB | 1 |
| Arumugam, P; Memmott, MJ; Saint, KJ; Tonge, CM | 1 |
| Kaandorp, TAM; Kuijpers, D; Oudkerk, M; van der Harst, P; van Dijk, R; van Dijkman, PRM; Vliegenthart, R | 1 |
| Andrikopoulou, E; Bajaj, NS; Brice, L; Doppalapudi, H; Hage, FG; Iskandrian, AE; Morgan, CJ | 1 |
| Aden, JK; Lisanti, CJ; Minor, MR; Steel, KE; Thomas, DM | 1 |
| Bober, R; Edward, JA; Lee, JH; Morin, DP; White, CJ | 1 |
| Aaronson, K; Colvin, M; Corbett, JR; Ghannam, M; Koelling, T; Konerman, MC; Lazarus, JJ; Murthy, VL; Pagani, F; Saleh, A; Weinberg, RL | 1 |
| Babar, AK; Bui, L; DeGolovine, A; Gould, KL; Johnson, NP; Kitkungvan, D; Kumar, S; Madjid, M; Nacimbene, A; Patel, MB; Roby, AE; Vejpongsa, P | 1 |
| Borah, P; Deb, PK; Deka, S; Mailavaram, RP | 1 |
| Carafa, MRP; Flammia, FC; Larici, AR; Lo Piccolo, F; Marano, R; Meduri, A; Merlino, B; Natale, L; Rovere, G; Savino, G | 1 |
| García Gonzalez, MP; Higueras Ortega, L; Lopez-Lereu, MP; Maceira Gonzalez, AM; Monmeneu Menadas, JV | 1 |
| Kero, T; Knuuti, J; Lagerqvist, B; Lubberink, M; Pikkarainen, E; Saraste, A; Sörensen, J | 1 |
| Caobelli, F; Clerc, OF; Frey, SM; Haaf, P; Honegger, U; Zellweger, MJ | 1 |
10 review(s) available for regadenoson and adenosine
| Article | Year |
|---|---|
Adenosine A2A receptor as a drug discovery target.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Crystallography, X-Ray; Drug Discovery; Humans; Ligands; Protein Conformation; Receptor, Adenosine A2A; Signal Transduction | 2014 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in pharmacologic agents in imaging: new A2A receptor agonists.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Coronary Vessels; Cyclohexanecarboxylic Acids; Dipyridamole; Heart; Humans; Organotechnetium Compounds; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2006 |
Current methods of pharmacologic stress testing and the potential advantages of new agents.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Coronary Disease; Dobutamine; Exercise Test; Humans; Positron-Emission Tomography; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2009 |
Current advances in vasodilator pharmacological stress perfusion imaging.
Topics: Adenosine; Adult; Contraindications; Coronary Artery Disease; Dipyridamole; Exercise Test; Female; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles; Radiopharmaceuticals; Vasodilator Agents | 2009 |
[A novel way to induce coronary hyperaemia].
Topics: Adenosine; Coronary Angiography; Coronary Stenosis; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Purines; Pyrazoles | 2013 |
Magnetic resonance stress imaging of myocardial perfusion and wall motion.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Cardiotonic Agents; Coronary Angiography; Dipyridamole; Exercise Test; Humans; Magnetic Resonance Imaging; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2014 |
Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.
Topics: Adenosine; Aged; Atrioventricular Block; Coronary Artery Disease; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2019 |
P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future.
Topics: Adenosine; Asthma; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ligands; Neoplasms; Parkinson Disease; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Pyrazoles; Receptors, Purinergic P1 | 2019 |
Practical instructions for using drugs in CT and MR cardiac imaging.
Topics: Adenosine; Adrenergic beta-Antagonists; Anti-Anxiety Agents; Atropine; Calcium Channel Blockers; Cardiac Imaging Techniques; Computed Tomography Angiography; Contraindications, Drug; Coronary Angiography; Coronary Vessels; Dipyridamole; Dobutamine; Heart; Humans; Ivabradine; Magnetic Resonance Imaging; Nitroglycerin; Purines; Pyrazoles; Vasodilator Agents | 2021 |
8 trial(s) available for regadenoson and adenosine
| Article | Year |
|---|---|
Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Electrocardiography; Heart; Humans; Myocardial Ischemia; Organophosphorus Compounds; Organotechnetium Compounds; Pilot Projects; Purines; Pyrazoles; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon | 2005 |
Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus.
Topics: Adenosine; Adolescent; Adult; Aged; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Male; Middle Aged; Organization and Administration; Prognosis; Purines; Pyrazoles; Vasodilator Agents; Young Adult | 2009 |
Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Index; Coronary Circulation; Diabetes Complications; Double-Blind Method; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Obesity; Patient Satisfaction; Predictive Value of Tests; Purines; Pyrazoles; Risk Assessment; Risk Factors; Sex Factors; Tomography, Emission-Computed, Single-Photon | 2008 |
Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.
Topics: Adenosine; Coronary Artery Disease; Coronary Circulation; Double-Blind Method; Heart Ventricles; Humans; Infusions, Intravenous; Linear Models; Myocardial Ischemia; Myocardial Perfusion Imaging; Predictive Value of Tests; Prospective Studies; Purines; Pyrazoles; Severity of Illness Index; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents; Ventricular Dysfunction, Left | 2009 |
The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adult; Body Mass Index; Contrast Media; Coronary Circulation; Drug Dosage Calculations; Female; Humans; Hyperemia; Infusions, Intravenous; Injections, Intravenous; Magnetic Resonance Imaging, Cine; Male; Meglumine; Middle Aged; Myocardial Perfusion Imaging; Obesity; Organometallic Compounds; Predictive Value of Tests; Purines; Pyrazoles; Time Factors; Utah; Vasodilator Agents | 2012 |
Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Double-Blind Method; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents; Ventricular Dysfunction, Left | 2015 |
Intravenous regadenoson with aminophylline reversal is safe and equivalent to intravenous adenosine infusion for fractional flow reserve measurements.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aminophylline; Cardiotonic Agents; Coronary Angiography; Coronary Stenosis; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Fractional Flow Reserve, Myocardial; Humans; Infusions, Intravenous; Male; Middle Aged; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; Vasodilator Agents | 2018 |
Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Caffeine; Cardiovascular Diseases; Coronary Circulation; Dipyridamole; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles | 2019 |
36 other study(ies) available for regadenoson and adenosine
| Article | Year |
|---|---|
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Amino Acids; Animals; Binding Sites; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; HEK293 Cells; Humans; Ligands; Models, Molecular; Nucleosides; Phenethylamines; Protein Conformation; Radioligand Assay; Receptor, Adenosine A2A; Stereoisomerism; Structure-Activity Relationship; Thermodynamics | 2012 |
Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A
Topics: Adenosine; Cyclic AMP; Dose-Response Relationship, Drug; Drug Design; HEK293 Cells; Humans; Hydrazines; Ligands; Molecular Structure; Receptor, Adenosine A2A; Structure-Activity Relationship | 2019 |
Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists.
Topics: Adenosine; Animals; Antihypertensive Agents; Coronary Vessels; Corpus Striatum; Cyclic AMP; Dose-Response Relationship, Drug; Female; Humans; Male; PC12 Cells; Phenethylamines; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Rats; Receptor, Adenosine A2A; Receptors, Purinergic P1; Swine; Triazines; Triazoles; Vasodilation; Vasodilator Agents | 2001 |
Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs.
Topics: Adenosine; Animals; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Vessels; Dogs; Heart; Heart Rate; Kidney; Mesenteric Arteries; Purinergic P1 Receptor Agonists; Purines; Pyrazoles; Receptor, Adenosine A2A; Receptors, Purinergic P1; Vasodilation; Vasodilator Agents | 2003 |
New stress test agents reduce adverse effects.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Exercise Test; Humans; Purines; Pyrazoles; Vasodilator Agents | 2008 |
Lessons from the development of new adenosine A2A receptor agonists.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Coronary Circulation; Humans; Image Interpretation, Computer-Assisted; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Purines; Pyrazoles; Reproducibility of Results; Tomography, Emission-Computed, Single-Photon | 2008 |
Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.
Topics: Acute Disease; Adenosine; Adenosine A2 Receptor Agonists; Animals; Blood Flow Velocity; Chronic Disease; Coronary Circulation; Coronary Stenosis; Disease Models, Animal; Dogs; Hyperemia; Infusions, Intravenous; Injections, Intravenous; Metabolic Clearance Rate; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Purines; Pyrazoles; Radiopharmaceuticals; Receptor, Adenosine A2A; Technetium Tc 99m Sestamibi; Thallium Radioisotopes; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2009 |
Connectivity of radiotracers to vasodilators is thallium the missing link?
Topics: Acute Disease; Adenosine; Adenosine A2 Receptor Agonists; Animals; Blood Flow Velocity; Chronic Disease; Coronary Circulation; Coronary Stenosis; Dogs; Humans; Hyperemia; Infusions, Intravenous; Injections, Intravenous; Metabolic Clearance Rate; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Purines; Pyrazoles; Radiopharmaceuticals; Receptor, Adenosine A2A; Technetium Tc 99m Sestamibi; Thallium Radioisotopes; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2009 |
Regadenoson.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Coronary Artery Disease; Coronary Circulation; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles | 2010 |
Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome.
Topics: Adenosine; Adolescent; Adult; Aged; Blood Pressure; Diabetes Mellitus; Female; Heart Rate; Humans; Hyperglycemia; Male; Metabolic Syndrome; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Young Adult | 2010 |
An example of the clinical selectivity of regadenoson for the A2a adenosine receptor.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Aged; Biomarkers, Pharmacological; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Exercise Test; Humans; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Receptor, Adenosine A2A; Vasodilator Agents | 2009 |
Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Female; Heart Transplantation; Hemodynamics; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2011 |
The crux of maximum hyperemia: the last remaining barrier for routine use of fractional flow reserve.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Coronary Stenosis; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Purines; Pyrazoles; Vasodilator Agents | 2011 |
Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Cause of Death; Chi-Square Distribution; Female; Heart Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Predictive Value of Tests; Prognosis; Propensity Score; Proportional Hazards Models; Purines; Pyrazoles; Reference Values; Risk Factors; Stroke Volume; Time Factors; Vasodilator Agents; Ventricular Function, Left | 2012 |
Comparing prognostic value of imaging agents and imaging techniques.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Female; Heart Diseases; Humans; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2012 |
Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Blood Pressure; Female; Fractional Flow Reserve, Myocardial; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Purines; Pyrazoles | 2013 |
Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
Topics: Adenosine; Coronary Artery Disease; Data Collection; Dipyridamole; Health Personnel; Humans; Myocardial Perfusion Imaging; Nuclear Medicine Department, Hospital; Purines; Pyrazoles; Receptor, Adenosine A2A; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Use of regadenoson for measurement of fractional flow reserve.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Cardiac Catheterization; Coronary Angiography; Coronary Stenosis; Female; Fractional Flow Reserve, Myocardial; Hemodynamics; Humans; Hyperemia; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Predictive Value of Tests; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Severity of Illness Index; Vasodilator Agents | 2014 |
Exploratory use of cardiovascular magnetic resonance imaging in liver transplantation: a one-stop shop for preoperative cardiohepatic evaluation.
Topics: Adenosine; Adult; Cardiovascular Diseases; Contrast Media; Coronary Angiography; Dobutamine; Feasibility Studies; Female; Humans; Liver Diseases; Liver Transplantation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Preoperative Care; Purines; Pyrazoles | 2013 |
Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.
Topics: Adenosine; Coronary Circulation; Dipyridamole; Female; Healthy Volunteers; Heart Rate; Humans; Infusions, Parenteral; Magnetic Resonance Imaging; Male; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Vasodilation; Vasodilator Agents; Young Adult | 2013 |
Is regadenoson an appropriate stressor for MPI in patients with left bundle branch block or pacemakers?
Topics: Adenosine; Blood Pressure; Bundle-Branch Block; Exercise Test; Heart Rate; Humans; Myocardial Perfusion Imaging; Pacemaker, Artificial; Purines; Pyrazoles | 2013 |
Regadenoson for FFR: time to say good-bye to adenosine?
Topics: Adenosine; Adenosine A2 Receptor Agonists; Cardiac Catheterization; Coronary Stenosis; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Purines; Pyrazoles; Vasodilator Agents | 2014 |
Incremental value of pharmacological stress cardiac dual-energy CT over coronary CT angiography alone for the assessment of coronary artery disease in a high-risk population.
Topics: Adenosine; Cardiac Catheterization; Cardiac-Gated Imaging Techniques; Contrast Media; Coronary Angiography; Coronary Artery Disease; Exercise Test; Female; Humans; Iopamidol; Male; Middle Aged; Prospective Studies; Purines; Pyrazoles; Radiation Dosage; Radiographic Image Interpretation, Computer-Assisted; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Variability of fractional flow reserve according to the methods of hyperemia induction.
Topics: Adenosine; Aged; Coronary Artery Disease; Coronary Circulation; Female; Fractional Flow Reserve, Myocardial; Hemodynamics; Humans; Hyperemia; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Middle Aged; Nicorandil; Purines; Pyrazoles; Radiography; Reproducibility of Results; Vasodilator Agents | 2015 |
Splenic Switch-off: A Tool to Assess Stress Adequacy in Adenosine Perfusion Cardiac MR Imaging.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Cardiac Imaging Techniques; Dobutamine; Exercise Test; Humans; Magnetic Resonance Angiography; Middle Aged; Perfusion; Purines; Pyrazoles; Retrospective Studies; Spleen; Young Adult | 2015 |
Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.
Topics: Adenosine; Coronary Artery Disease; Death, Sudden, Cardiac; Exercise Test; Female; Humans; Incidence; Male; Middle Aged; Myocardial Perfusion Imaging; North Carolina; Prevalence; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Vasodilator Agents | 2015 |
Vasodilator stress with adenosine and the gender preponderance for tolerability and manifestation of adverse symptoms: Is there a physiological basis?
Topics: Adenosine; Cardiology; Exercise Test; Female; Humans; Image Processing, Computer-Assisted; Male; Nuclear Medicine; Purines; Pyrazoles; Sex Factors; Vasodilator Agents | 2015 |
Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing.
Topics: Adenosine; Cohort Studies; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Purines; Pyrazoles; Retrospective Studies | 2015 |
Role of Perfusion at Rest in the Diagnosis of Myocardial Infarction Using Vasodilator Stress Cardiovascular Magnetic Resonance.
Topics: Adenosine; Aged; Chronic Disease; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Purines; Pyrazoles; Rest; Retrospective Studies; Vasodilator Agents | 2016 |
Impact of pharmacological stress agent on patient motion during rubidium-82 myocardial perfusion PET/CT.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Coronary Circulation; Female; Humans; Male; Middle Aged; Motion; Myocardial Perfusion Imaging; Positron Emission Tomography Computed Tomography; Purines; Pyrazoles; Respiration; Retrospective Studies; Rubidium Radioisotopes | 2018 |
Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping.
Topics: Adenosine; Aged; Caffeine; Coffee; Coronary Artery Disease; Coronary Circulation; Female; Humans; Hyperemia; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Pyrazoles; Reproducibility of Results; Time Factors; Vasodilator Agents | 2017 |
Effects of adenosine and regadenoson on hemodynamics measured using cardiovascular magnetic resonance imaging.
Topics: Adenosine; Adult; Coronary Circulation; Female; Healthy Volunteers; Heart Rate; Heart Ventricles; Hemodynamics; Humans; Magnetic Resonance Imaging, Cine; Male; Predictive Value of Tests; Prospective Studies; Purines; Pyrazoles; Stroke Volume; Time Factors; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right | 2017 |
Safety of regadenoson positron emission tomography stress testing in orthotopic heart transplant patients.
Topics: Adenosine; Aged; Blood Pressure; Electrocardiography; Exercise Test; Female; Heart Transplantation; Hemodynamics; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Patient Safety; Positron-Emission Tomography; Purines; Pyrazoles; Retrospective Studies; Risk Factors; Stress, Mechanical; Transplant Recipients; Vascular Diseases | 2020 |
Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: Data from a multicentre prospective registry.
Topics: Adenosine; Humans; Magnetic Resonance Spectroscopy; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Registries; Vasodilator Agents | 2022 |
Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease.
Topics: Adenosine; Arteries; Coronary Artery Disease; Coronary Circulation; Humans; Hyperemia; Myocardial Perfusion Imaging; Perfusion; Positron-Emission Tomography; Purines; Pyrazoles; Water | 2022 |
Left ventricular ejection fraction, myocardial blood flow and hemodynamic variables in adenosine and regadenoson vasodilator 82-Rubidium PET.
Topics: Adenosine; Coronary Artery Disease; Coronary Circulation; Hemodynamics; Humans; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles; Rubidium; Stroke Volume; Vasodilator Agents; Ventricular Function, Left | 2022 |